LRMR241220C5000
- 0.09
- +0.04+80.00%
Larimar Therapeutics Newsroom
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $14 to $36
Larimar Therapeutics Announces Initial Data From OLE Study of Nomlabofusp
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Recommends Buy on Larimar Therapeutics Amid Misinterpreted Data and Overreaction
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
Crude Oil Down 1%; Webuy Global Shares Spike Higher
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Promising Developments and Strategic Regulatory Support Justify Buy Rating for Larimar Therapeutics
Larimar Therapeutics Analyst Ratings
Larimar Therapeutics Stock Plunges on Clinical Study Concerns
Larimar Therapeutics Shares Resume Trade
Larimar Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -41.8%
Express News | Larimar Therapeutics Inc: Projected Runway Into Q2 of 2026
Express News | Larimar Therapeutics Inc - Bla Submission Targeted for 2H 2025 for Potential Accelerated Approval
Express News | Larimar Therapeutics Inc - Nomlabofusp 25 Mg Well Tolerated in 14 Participants for up to 260 Days